BBP-631 is a gene therapy commercialized by BridgeBio Pharma, with a leading Phase II program in Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of BBP-631’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for BBP-631 is expected to reach an annual total of $119 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
BBP-631 is under development for the treatment of congenital adrenal hyperplasia 21-hydroxylase deficiency. The therapeutic candidate comprises of an adeno-associated virus 5 (AAV5) carrying cytochrome P450 family 21 subfamily A member 2 (CYP21A2) gene and administered through intravenous route.
BridgeBio Pharma Overview
BridgeBio Pharma (BridgeBio) is a clinical-stage biotechnology company that develops novel medicines for genetic diseases. The company’s pipeline product portfolio includes precision cardiorenal drugs such as acoramidis, encaleret, BBP-711; mendelian disease drugs which include acoramidis, fosdenopterin, patidegib topical gel, low-dose infigratnib, BBP-589, BBP-551, BBP-418, BBP-681, BBP-671, among others; precision oncology drugs which include high-dose infigratinib, BBP-398, BBP-454, BBP-954. BridgeBio also carries out various phases of clinical trials such as pre-clinical, phase I, phase II studies. The company’s academic partners which include Medical University of South Carolina, University of Pittsburgh, Oregon Health, and Science University, among others. Its industry partners which include Helsinn, Alexion, Bristol Myers Squibb, among others. BridgeBio is headquartered in Palo Alto, California, the US.
The company reported revenues of (US Dollars) US$69.7 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$8.3 million in FY2020. The operating loss of the company was US$576.6 million in FY2021, compared to an operating loss of US$474.5 million in FY2020. The net loss of the company was US$562.5 million in FY2021, compared to a net loss of US$448.7 million in FY2020. The company reported revenues of US$0.3 million for the third quarter ended September 2022, a decrease of 99.5% over the previous quarter.
For a complete picture of BBP-631’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.